DepoMed (DEPO +34.3%) was Nasdaq's top gainer after announcing Friday that the FDA approved its...

|By:, SA News Editor

DepoMed (DEPO +34.3%) was Nasdaq's top gainer after announcing Friday that the FDA approved its Gralise treatment for pain associated with shingles, but who's going to distribute it? DepoMed's partner, Abbott Labs (ABT -0.7%), apparently doesn't plan to launch it even though DepoMed says it's obligated to do so. The companies are headed to mediation over the dispute.